Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Adolor Corporation (“Adolor” or the “Company”) (Nasdaq: ADLR) relating to the proposed acquisition Cubist Pharmaceuticals, Inc. (“Cubist”). Under the terms of the transaction Adolor shareholders would receive $4.25 in cash and one Contingent Payment Right entitling the holder to receive additional cash payment payments of up to $4.50, if certain benchmarks are achieved, for each share of Adolor stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Adolor for not acting in the Adolor shareholders' best interests in connection with the sale process to Cubist. The transaction may undervalue Adolor as a result of failing to adequately shop the Company. If you own shares of Adolor stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at email@example.com, visiting http://brodsky-smith.com/348-adlr-adolor-corporation.html, or by calling toll free 877-LEGAL-90.